ReCode Therapeutics to Present Preclinical Data from mRNA-based Program for Cystic Fibrosis at Upcoming Virtual 2021 North American Cystic Fibrosis Conference

Oct. 19, 2021 12:00 UTC



MENLO PARK, Calif. & DALLAS--(BUSINESS WIRE)-- ReCode Therapeutics, a biopharmaceutical company pioneering disease-modifying genetic medicines using its proprietary LNP delivery platform, today announced that it will present preclinical data from its mRNA-based therapeutic program for cystic fibrosis (CF) in a poster presentation at the upcoming 2021 North American Cystic Fibrosis Conference (NACFC) to be held virtually from November 2-5, 2021.

Details are as follows:

Poster: Variant-Agnostic CFTR Rescue After Aerosolized Delivery of CFTR mRNA Formulated With a SORT-LNP in Primary Human Bronchial Epithelial Cells Derived From Patients With Cystic Fibrosis
Presenter: Michael Torres, Ph.D., Vice President, R&D, ReCode Therapeutics
Poster Number: 583
Date: Wednesday, November 3, 2021
Live Poster Session: 1:10 – 1:50 p.m. ET

Dr. Torres will also present during a workshop session titled, “W05--PTC-GMS: Approaches for Delivery of Nucleotide Based Therapeutics” on Wednesday, November 3, 2021 from 11:00 a.m. – 1:00 p.m. ET.

About ReCode Therapeutics
ReCode Therapeutics (the “Company”) is an integrated genetic medicines company developing disease-modifying therapeutics using its powerful LNP delivery technology to target organs and tissues beyond the liver. The Company’s pipeline includes lead programs for patients with life-limiting genetic respiratory diseases, including cystic fibrosis and primary ciliary dyskinesia. The Company is leveraging its proprietary LNP platform and nucleic acid technologies and utilizing systemic and direct delivery for mRNA-mediated replacement and gene editing/correction in target cells, including stem cells. For more information, visit and follow us on Twitter @ReCodeTx and LinkedIn.


Media Contact:
Will Zasadny
Canale Communications, Inc.
(619) 961-8848

Investor Contact:
Sarah McCabe
Stern Investor Relations


Source: ReCode Therapeutics

Back to news